Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.


CSE:AGN - Post by User

Comment by TheBearInTheWoodson Jul 09, 2022 2:47pm
120 Views
Post# 34813041

RE:RE:RE:RE:Trading below PP

RE:RE:RE:RE:Trading below PP
TheBearInTheWoods wrote: When I was a newer investor, I used plays like AGN to learn. You can trade plays like AGN, But I dont invest in companies that Management doesnt.

Next time dont beat up on critical posts and take some time to do some research,

GLTA



TheBearInTheWoods wrote: Your correct, missed that NR. I stand by the rest of the post though, The company has 120 mil shares outstanding and 40 million warrants.... 

Comparing BLU and AGN is interesting

AGN - Rights?

Shares Outstanding - 120,000,000
Warrants Remaining - 40,000,000!!!
Insider Holding - 2%
Insider Buying - $30,000

BLU - Owns a Drug and Commercialization

Shares Outstanding - 60,000,000
Warrants Remaining - 0 
Insider Holding - 33%
Insider Buying - $274,000

Lets Throw in ARCH for fun - Owns a Drug and Commercialization

Shares Outstanding - 58,000,000
Warrants Remaining - 0 
Insider Holding - 55%
Insider Buying - $282,000

You can tell alot about how Management will treat you based on what they personally have in the play... These numbers speak for themselves.

One question I have with this play though, if someone can answer and provide a link is: Does AGN own a patent or License to distribute in Canada? BLU owns a drug and can commercialize it as does ARCH . AGN is repurposing a drug that has previously been approved in South korea and Japan decades ago, I have had difficulty digging up the rights AGN has to the drug itself.

Once again, I want you guys to make money I just like to dive into the details. Maybe I will buy some AGN but I cant find clarity on the rights and if AGN only has rights to Canada for instance than there isnt much of a market.




<< Previous
Bullboard Posts
Next >>